Compare VNDA & AMCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNDA | AMCX |
|---|---|---|
| Founded | 2002 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Cable & Other Pay Television Services |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 441.5M | 427.9M |
| IPO Year | 2006 | 2011 |
| Metric | VNDA | AMCX |
|---|---|---|
| Price | $8.10 | $7.94 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 4 | 5 |
| Target Price | ★ $13.63 | $6.50 |
| AVG Volume (30 Days) | ★ 2.8M | 363.7K |
| Earning Date | 02-12-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $212,074,000.00 | ★ $2,316,303,000.00 |
| Revenue This Year | $12.01 | N/A |
| Revenue Next Year | $24.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.12 | N/A |
| 52 Week Low | $3.81 | $5.41 |
| 52 Week High | $9.60 | $10.60 |
| Indicator | VNDA | AMCX |
|---|---|---|
| Relative Strength Index (RSI) | 61.30 | 29.79 |
| Support Level | $7.14 | $7.67 |
| Resistance Level | $7.82 | $8.61 |
| Average True Range (ATR) | 0.44 | 0.31 |
| MACD | -0.05 | -0.15 |
| Stochastic Oscillator | 62.09 | 13.87 |
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
AMC Networks owns several linear pay-TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network, reached 60 million pay-TV households in the US at the end of 2024. The firm also had nearly 12.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.